doxapram and Birth Weight
doxapram has been researched along with Birth Weight in 5 studies
Doxapram: A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225)
doxapram : A member of the class of pyrrolidin-2-ones that is N-ethylpyrrolidin-2-one in which both of the hydrogens at the 3 position (adjacent to the carbonyl group) are substituted by phenyl groups, and one of the hydrogens at the 4 position is substituted by a 2-(morpholin-4-yl)ethyl group. A central and respiratory stimulant with a brief duration of action, it is used (generally as the hydrochloride or the hydrochloride hydrate) as a temporary treatment of acute respiratory failure, particularly when superimposed on chronic obstructive pulmonary disease, and of postoperative respiratory depression. It has also been used for treatment of postoperative shivering.
Birth Weight: The mass or quantity of heaviness of an individual at BIRTH. It is expressed by units of pounds or kilograms.
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
"Fifteen infants, median gestational age at birth 27 weeks (range 24-30), age at study 27 days (12-60), with >/=6 episodes of bradycardia or hypoxaemia/6 h despite serum caffeine levels in the therapeutic range, received doxapram either intravenously (0." | 9.09 | Effect of doxapram on episodes of apnoea, bradycardia and hypoxaemia in preterm infants. ( Bohnhorst, B; Darraj, S; Poets, CF, 1999) |
"Twelve premature infants with significant apnea of prematurity while receiving therapeutic doses of aminophylline were given an intravenous infusion of doxapram, 2 or 2." | 7.67 | Physiologic effects of doxapram in idiopathic apnea of prematurity. ( Barrington, KJ; Barton, J; Finer, NN; Peters, KL, 1986) |
"Fifteen infants, median gestational age at birth 27 weeks (range 24-30), age at study 27 days (12-60), with >/=6 episodes of bradycardia or hypoxaemia/6 h despite serum caffeine levels in the therapeutic range, received doxapram either intravenously (0." | 5.09 | Effect of doxapram on episodes of apnoea, bradycardia and hypoxaemia in preterm infants. ( Bohnhorst, B; Darraj, S; Poets, CF, 1999) |
"Doxapram is a treatment option for severe apnea of prematurity (AOP)." | 3.91 | Doxapram Treatment and Diaphragmatic Activity in Preterm Infants. ( de Jongh, FH; de Waal, CG; Hutten, GJ; Kraaijenga, JV; van Kaam, AH, 2019) |
"Doxapram is a respiratory stimulant widely used for the treatment of idiopathic apnea of prematurity, although it has been demonstrated that it can induce a transient decrease of cerebral blood flow and that isolated mental delay in infants weighing <1,250 g is associated with the total dosage and duration of doxapram therapy." | 3.73 | Brain hemodynamic effects of doxapram in preterm infants. ( Bertini, G; Dani, C; Filippi, L; Pezzati, M; Pratesi, S; Rubaltelli, FF; Tronchin, M, 2006) |
"Twelve premature infants with significant apnea of prematurity while receiving therapeutic doses of aminophylline were given an intravenous infusion of doxapram, 2 or 2." | 3.67 | Physiologic effects of doxapram in idiopathic apnea of prematurity. ( Barrington, KJ; Barton, J; Finer, NN; Peters, KL, 1986) |
Research
Studies (5)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (40.00) | 18.7374 |
1990's | 1 (20.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 1 (20.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
de Waal, CG | 1 |
Hutten, GJ | 1 |
Kraaijenga, JV | 1 |
de Jongh, FH | 1 |
van Kaam, AH | 1 |
Dani, C | 1 |
Bertini, G | 1 |
Pezzati, M | 1 |
Pratesi, S | 1 |
Filippi, L | 1 |
Tronchin, M | 1 |
Rubaltelli, FF | 1 |
Poets, CF | 1 |
Darraj, S | 1 |
Bohnhorst, B | 1 |
Barrington, KJ | 1 |
Finer, NN | 1 |
Peters, KL | 1 |
Barton, J | 1 |
Gupta, PK | 1 |
Moore, J | 1 |
Trials
1 trial available for doxapram and Birth Weight
Article | Year |
---|---|
Effect of doxapram on episodes of apnoea, bradycardia and hypoxaemia in preterm infants.
Topics: Apnea; Birth Weight; Bradycardia; Caffeine; Doxapram; Drug Resistance; Gestational Age; Humans; Hypo | 1999 |
Other Studies
4 other studies available for doxapram and Birth Weight
Article | Year |
---|---|
Doxapram Treatment and Diaphragmatic Activity in Preterm Infants.
Topics: Apnea; Birth Weight; Diaphragm; Doxapram; Electromyography; Female; Gestational Age; Humans; Infant, | 2019 |
Brain hemodynamic effects of doxapram in preterm infants.
Topics: Apnea; Birth Weight; Blood Flow Velocity; Brain; Case-Control Studies; Doxapram; Gestational Age; Hu | 2006 |
Physiologic effects of doxapram in idiopathic apnea of prematurity.
Topics: Aminophylline; Apnea; Birth Weight; Blood Pressure; Carbon Dioxide; Doxapram; Gestational Age; Human | 1986 |
The use of doxapram in the newborn.
Topics: Anesthesia, Obstetrical; Bicarbonates; Birth Weight; Blood; Carbon Dioxide; Doxapram; Female; Gestat | 1973 |